VanEck Vectors Biotech ETF

Most Recent

  • uploads///PE and share price
    Company & Industry Overviews

    Pfizer’s Medivation Acquisition: What You Need to Know

    On August 22, Medivation (MDVN) and Pfizer (PFE) entered into a definitive agreement. Pfizer will acquire Medivation for a consideration of ~$14 billion.

    By Jillian Dabney
  • Healthcare

    Third Point Partners ups stake in Amgen

    The fund noted in its letter that “Amgen has all the hallmarks of a hidden value situation, which is one of the fund’s favorite investment themes.”

    By Samantha Nielson
  • uploads///Chart
    Company & Industry Overviews

    What Drove Ionis’s Revenue in Q1

    In the first quarter, leading biopharmaceutical company Ionis Pharmaceuticals’ (IONS) revenue grew 24.7% year-over-year to $144.4 million from $115.8 million.

    By Mike Benson
  • uploads///ousa chea  unsplash
    Healthcare

    BlueBird Bio Stock Jumps over 6% on May 17

    BlueBird Bio stock has risen ~119.9% over the last 12 months and 6.3% year-to-date.

    By Mike Benson
  • uploads///ANR
    Earnings Report

    BioMarin: Why So Many ‘Buy’ Recommendations?

    BioMarin (BMRN) is expected to report 2Q16 earnings on August 4, 2016. “Buy” ratings have increased to 94.7% from 90% on June 29, 2016.

    By Jillian Dabney
  • uploads///hospital _
    Earnings Report

    Allergan’s 1Q18 Earnings: Analysts’ Estimates

    Allergan (AGN) plans to release its 1Q18 earnings on April 30. Wall Street expect AGN’s earnings per share to reach $3.36.

    By Mike Benson
  • uploads///chemist _
    Healthcare

    Why Sesen Bio Stock Jumped Over 37% this Week

    Sesen Bio (SESN), formerly known as Eleven Biotherapeutics, is developing next-generation antibody-drug conjugate therapies. The stock jumped ~26.1% to $2.27 yesterday.

    By Mike Benson
  • uploads///Graph
    Miscellaneous

    Which Biotechnology Companies Could Benefit from Brexit?

    The weak pound is expected to negatively affect biotechnology companies with a high revenue exposure to the United Kingdom.

    By Margaret Patrick
  • uploads///dna _
    Earnings Report

    Allergan Beats EPS and Revenue Estimates: Q3 2018 Earnings

    Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Recommendations for Shire as of October 30

    Analysts’ estimates show that Shire (SHPG) stock has a potential to return ~15.8% over the next 12 months.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Amgen: Expect Nearly Flat Revenues in Q3

    New products are expected to deliver double-digit growth, while legacy brands are expected to offset the growth during the quarter.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Allergan’s Q3 2018 Estimates: Revenue Decline Expected

    Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decline 3.8% to $3.88 billion.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Biogen: Analysts’ Recommendations on October 19

    For Biogen, eight analysts recommended a “strong buy,” 12 recommended a “buy,” and nine recommended a “hold.”

    By Mike Benson
  • uploads///NBIX
    Company & Industry Overviews

    Analysts Are Mostly Positive on Neurocrine Biosciences

    On October 4, Neurocrine Biosciences (NBIX) stock closed at $114.58, which is an ~3.79% decline from its October 3 close of $119.09.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s Stock Performance and Estimates for Q3 2018

    Wall Street analysts expect Allergan to report EPS of $3.98 on revenues of $3.8 billion in the third quarter.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Valuations on September 28

    Ionis reported revenues of $118.0 million during the second quarter for 5.0% growth in year-over-year revenues compared to the second quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s Developments in September

    On September 20, Allergan (AGN) announced a partnership with actor Scott Eastwood to encourage the recognition of World Alzheimer’s Day on September 21.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Estimates and Recommendations for Shire on September 19

    Wall Street analysts expect Shire (SHPG) to report a 2.7% rise in revenue to ~$15.56 billion in 2018 compared to ~$15.16 billion in 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Bluebird Bio’s Data for Lenti-D Investigational Gene Therapy

    Bluebird Bio (BLUE) released on September 5 its updated data from the Phase 2/3 Starbeam study evaluating investigational Lenti-D gene therapy.

    By Mike Benson
  • uploads///laboratory _
    Company & Industry Overviews

    A Look at Incyte’s Valuation on August 22

    On August 22, Incyte was trading at a forward price-to-earnings multiple of 38.1x compared to the industry average of ~13.9x.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Examining Amgen’s Revenue Trend in Q2 2018

    Amgen reported a 4% rise in its year-over-year revenue to ~$6.06 billion in the second quarter compared to $5.81 billion in the first quarter of 2017.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Considering Allergan’s Q2 2018 Revenue Trend

    As discussed earlier, Allergan (AGN) reported a 2.9% rise in its YoY (year-over-year) revenue to $4.1 billion in the second quarter.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What’s Ionis Pharmaceuticals’ Valuation after Q2 Results?

    Ionis Pharmaceuticals (IONS), a leading RNA-targeted therapeutics developing company, aims to develop best-in-class drugs for life-threatening diseases.

    By Mike Benson
  • uploads///dna _
    Earnings Report

    Bluebird Bio Misses Analysts’ Estimates in Q2 2018

    Clinical-stage biotechnology company Bluebird Bio (BLUE) released its Q2 2018 results yesterday, missing analysts’ revenue and EPS estimates.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    What Analysts Recommend for Bluebird Bio Stock

    As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter.

    By Mike Benson
  • uploads///thermometer _
    Earnings Report

    Shire’s Q2 2018 Earnings Beat Analyst Estimates

    Shire (SHPG) beat Wall Street analysts’ estimates for revenues and EPS. It reported non-GAAP EPS of $3.88 on revenues of $3.9 billion in Q2 2018.

    By Mike Benson
  • uploads///pulse trace _
    Healthcare

    TrovaGene Stock Fell 48% on June 8 after Pricing Announcement

    Following TrovaGene’s pricing announcement, the stock price decreased ~48% to the closing price of $0.92 on June 8.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Gilead Sciences: Analysts’ Estimates after 4Q17

    Gilead Sciences reported an EPS of $1.78 on revenues of $5.9 billion during 4Q17—an 18.7% decline in revenues compared to $7.3 billion in 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    A Look at Ionis’s 3Q17 Revenue Stream

    Ionis Pharmaceuticals (IONS) reported a 9% rise in its revenue to $120.9 million in 3Q17 compared to $110.9 million in 3Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Was Incyte’s Revenue Stream in 3Q17?

    Incyte’s total product royalty revenue was $44.5 million in 3Q17, a rise compared to $29.6 million in 3Q16.

    By Mike Benson
  • uploads///Chart  Rev
    Company & Industry Overviews

    Changes in Gilead’s Revenue Trends in 3Q17

    Gilead’s revenue Gilead Sciences (GILD) reported revenue of $6.5 billion in 3Q17, a 13% fall from the revenue of $7.5 billion seen in 3Q16. The 3Q17 figure includes product revenue of $6.4 billion, and royalty, contract, and other revenue of $110 million. Analysts expect revenue to fall ~21.9% to $5.7 billion in 4Q17. Geographical sales The above […]

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Behind Allergan’s Revenues in 3Q17

    For 3Q17, Allergan reported an 11.4% YoY (year-over-year) rise in revenues to $4.03 billion, compared with its revenues of $3.62 billion in 3Q16.

    By Mike Benson
  • uploads///A Fund details
    Healthcare

    Benefitting from IBB’s Lower Expense Ratio

    The iShares NASDAQ Biotechnology ETF (IBB) is an open-end fund with assets under management of $9.85 billion.

    By Peter Barnes
  • uploads///Chart  HIV HBV
    Company & Industry Overviews

    How Gilead’s HIV and HBV Portfolios Performed in 2Q17

    Gilead Sciences’ (GILD) portfolio includes various drugs for key therapeutic areas including HIV/AIDS, liver diseases, oncology, cardiovascular, inflammation, respiratory, and others.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Akcea Therapeutics’ Volanesorsen Performed in 2Q17

    Ionis Pharmaceuticals’ (IONS) Volanesorsen is a drug designed to reduce apoC-III protein production and lower triglycerides for patients with dyslipidemia.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Understanding Incyte’s 2Q17 Revenue Stream

    Incyte’s 2Q17 revenue growth was driven by the increased demand for Jakafi.

    By Mike Benson
  • uploads///Chart  EPS
    Company & Industry Overviews

    What’s Allergan’s Valuation after 2Q17 Earnings?

    Allergan reported an 8.8% increase in its 2Q17 revenues to $4.0 billion as compared to $3.7 billion in 2Q16.

    By Mike Benson
  • uploads///Analysts Recommendations
    Company & Industry Overviews

    Analysts’ Recommendations for Regeneron in July 2017

    In May 2017, Regeneron Pharmaceuticals (REGN) and Inovio Pharmaceuticals (INO) entered into an agreement for an immuno-oncology clinical study.

    By Daniel Collins
  • uploads///Chart  Dev
    Company & Industry Overviews

    Inside Allergan’s Developments in 2Q17

    Allergan (AGN) is a US-based pharmaceuticals company that deals in over-the-counter products, eye care products, and aesthetics products.

    By Mike Benson
  • uploads///Chart  AGN
    Miscellaneous

    A Look at Allergan’s Performance in 2Q17

    Allergan Headquartered in Dublin, Ireland, Allergan (AGN) is a leading pharmaceutical company focused on generic and specialty pharmaceutical products. The company has divided its business into three segments: US Specialized Therapeutics, US General Medicine, and International. Stock price performance Allergan’s stock price has risen ~1.4% in 2Q17, and 15.0% year-to-date as of July 7, 2017. […]

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Investor Update: Incyte’s Key Developments in 1Q17

    Incyte (INCY) distributes its key drug Jakafi through its own network of specialty pharmacy providers and wholesalers in the US.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Developments for Ionis Pharmaceuticals after 1Q17

    Ionis’s recent developments As discussed earlier, Ionis Pharmaceuticals (IONS) is focused on the development of drugs for the treatment of diseases with limited or no therapeutic options. Corporate developments In April 2017, Ionis entered into a collaborative agreement with Suzhou Ribo Life Science for the development and commercialization of RNA[1.ribonucleic acid]-targeted therapeutics in China. In […]

    By Mike Benson
  • uploads///Chart  Rev
    Earnings Report

    Inside Allergan’s 1Q17 Results: Revenue Streams

    Allergan (AGN) released its 1Q17 earnings on May 9, 2017, reporting a growth of 5.1% and revenues of ~$3.6 billion, as compared to $3.4 billion in 1Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Why These Collaborations Are Important to Incyte

    Incyte’s (INCY) Jakafi is distributed in the US markets through its network of specialty pharmacy providers and wholesalers for direct delivery to patients or patients’ pharmacies.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    What’s the Outlook for Gilead Sciences?

    Analysts are estimating that Gilead Sciences (GILD) will generate EPS (earnings per share) of $2.62 on sales of $7.1 billion in 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Gilead Sciences’ Valuation Compared to Its Peers

    As of December 30, 2016, Gilead Sciences (GILD) was trading at a forward PE multiple of ~6.9x compared to the industry average of 12.3x.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Why Valbenazine Studies Seem Promising

    In Neurocrine Biosciences’ (NBIX) phase three trial Kinect-3, investigational therapy Valbenazine has managed to demonstrate statistically significant improvement.

    By Margaret Patrick
  • uploads///Epclusa
    Company & Industry Overviews

    Epclusa: Gilead Sciences’s Pan-Genotype Product

    With its costly HCV drugs, Gilead Sciences (GILD) has one of the highest net margins in the biotechnology industry.

    By Jillian Dabney
  • uploads///Chart
    Company & Industry Overviews

    Understanding Allergan’s 3Q16 Revenue Stream

    As we discussed earlier, Allergan (AGN) reported revenues of $3.62 billion in its 3Q16 results—more than 4.5% revenue growth in 3Q16.

    By Mike Benson
  • uploads///orkambi revenue
    Earnings Report

    A Promising Uptake for Vertex’s Orkambi

    It’s been nine months since Vertex Pharmaceuticals (VRTX) launched Orkambi. Out of the 8,500 eligible patients, around 5,500 are using the drug.

    By Jillian Dabney
  • uploads///pegvaliase for PKU
    Company & Industry Overviews

    Understanding the Valuation Catalysts for BioMarin in 4Q16

    BioMarin plans to file a Biologics License Application with the FDA for Pegvaliase, which is indicated to treat phenylketonuria, by the end of fiscal 2016.

    By Jillian Dabney
  • uploads///non GAAP revenue
    Earnings Report

    The Story behind Medivation’s Rising Collaboration Revenue

    Medivation (MDVN) earned collaboration revenue from Xtandi’s US and non-US sales along with upfront and milestone payments.

    By Jillian Dabney
  • uploads///acquisitions
    Company & Industry Overviews

    Baxalta: Growth through Acquisitions

    In March 2013, Baxalta acquired Inspiration BioPharmaceuticals. Through this acquisition, it gained the investigational drug Obizur and related assets.

    By Jillian Dabney
  • uploads///EV TO EBITDA
    Company & Industry Overviews

    Why Is Medivation at a Premium on an EV-to-EBITDA Basis?

    On April 11, 2016, pharmaceutical company Medivation (MDVN) was trading at a forward EV-to-EBITDA multiple of 14.7x.

    By Jillian Dabney
  • uploads///Graph revenue breakdown
    Company & Industry Overviews

    BioMarin’s Business Model and Its 3 Sources of Revenue

    Let’s discuss BioMarin’s business model. It derives revenue from three sources, including product revenue. The latter accounts for ~98% of total revenue.

    By Jillian Dabney
  • uploads///Graph
    Earnings Report

    Repatha and Kyprolis Will Likely Become Blockbuster Drugs

    In 2015, Amgen (AMGN) managed to launch six new products in the US market. The company expects its cardiovascular drug Repatha to become a blockbuster drug.

    By Margaret Patrick
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.